metabolic dysfunction-associated steatohepatitis

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide for MASH

GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

Madrigal Pharmaceuticals Secures Three New Resmetirom U.S. Patents

CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...

By cGxPwire Editor
July 14, 2026

Bio-Pharma

GENFIT Secures U.S. Medicare Coverage for NASHnext Diagnostic Test

Lille, France; Cambridge, Massachusetts, United States; and Zurich, Switzerland, July 2, 2026 GENFIT announced that U.S. Medicare has approved...

By cGxPwire Editor
July 3, 2026

Bio-Pharma

PDS Biotechnology Presents Strong Immunotherapy and Translational Data Demonstrating Broad Immune Activation at SITC 2025

Princeton, New Jersey, November 10, 2025 — PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer...

By cGxPwire Editor
November 10, 2025

Bio-Pharma

Rivus Pharmaceuticals Reports Positive Phase 2 Results for HU6 in MASH Patients

CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering...